Increased lipolysis and energy expenditure in a mouse model with severely impaired glucagon secretion

PLoS ONE

Volumn 6, Issue 10, 2011, Pages

  Lou, Phing How ^a   Gustavsson, Natalia ^a,b   Wang, Yue ^a,b   Radda, George K ^a   Han, Weiping ^a,b  

^a AGENCY FOR SCIENCE   (Singapore)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

FATTY ACID; GLUCAGON; LIPID; SYNAPTOTAGMIN; SYNAPTOTAGMIN 7; UNCLASSIFIED DRUG; UNCOUPLING PROTEIN 3; INSULIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BASAL METABOLIC RATE; BODY FAT DISTRIBUTION; BODY WEIGHT; CALORIMETRY; CONTROLLED STUDY; ENERGY EXPENDITURE; FATTY ACID TRANSPORT; GENE EXPRESSION PROFILING; GLUCAGON RELEASE; LIPID METABOLISM; LIPOLYSIS; LUNG GAS EXCHANGE; MITOCHONDRION; MOUSE; NONHUMAN; OXYGEN CONSUMPTION; PHENOTYPE; PHYSICAL MODEL; PROTEIN LOCALIZATION; PROTEIN METABOLISM; SKELETAL MUSCLE; ANIMAL; ANIMAL MODEL; ENERGY METABOLISM; METABOLISM; MOUSE MUTANT; SECRETION;

MUS;

ANIMALS; ENERGY METABOLISM; FATTY ACIDS; GENE EXPRESSION PROFILING; GLUCAGON; INSULIN; LIPID METABOLISM; LIPOLYSIS; MICE; MICE, KNOCKOUT; MODELS, ANIMAL; SYNAPTOTAGMINS;

EID: 80055067640     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0026671     Document Type: Article

References (45)

1. Gustavsson N, Seah T, Lao Y, Radda GK, Sudhof TC, et al. (2011) Delayed onset of hyperglycaemia in a mouse model with impaired glucagon secretion demonstrates that dysregulated glucagon secretion promotes hyperglycaemia and type 2 diabetes. Diabetologia 54: 415-422.
2. Unger RH, (1985) Glucagon physiology and pathophysiology in the light of new advances. Diabetologia 28: 574-578.
3. Gustavsson N, Han W, (2009) Calcium-sensing beyond neurotransmitters: functions of synaptotagmins in neuroendocrine and endocrine secretion. Biosci Rep 29: 245-259.
4. Gustavsson N, Lao Y, Maximov A, Chuang JC, Kostromina E, et al. (2008) Impaired insulin secretion and glucose intolerance in synaptotagmin-7 null mutant mice. Proc Natl Acad Sci U S A 105: 3992-3997.
5. Gromada J, Franklin I, Wollheim CB, (2007) Alpha-cells of the endocrine pancreas: 35 years of research but the enigma remains. Endocr Rev 28: 84-116.
6. Gustavsson N, Wei SH, Hoang DN, Lao Y, Zhang Q, et al. (2009) Synaptotagmin-7 is a principal Ca2+ sensor for Ca2+-induced glucagon exocytosis in pancreas. J Physiol 587: 1169-1178.
7. Pang ZP, Sudhof TC, (2010) Cell biology of Ca2+-triggered exocytosis. Current opinion in cell biology 22: 496-505.
8. Sudhof TC, (2002) Synaptotagmins: why so many? J Biol Chem 277: 7629-7632.
9. Parker JC, Andrews KM, Allen MR, Stock JL, McNeish JD, (2002) Glycemic control in mice with targeted disruption of the glucagon receptor gene. Biochem Biophys Res Commun 290: 839-843.
10. Gelling RW, Du XQ, Dichmann DS, Romer J, Huang H, et al. (2003) Lower blood glucose, hyperglucagonemia, and pancreatic alpha cell hyperplasia in glucagon receptor knockout mice. Proc Natl Acad Sci U S A 100: 1438-1443.
11. Lee Y, Wang MY, Du XQ, Charron MJ, Unger RH, (2011) Glucagon receptor knockout prevents insulin-deficient type 1 diabetes in mice. Diabetes 60: 391-397.
12. Brand CL, Jorgensen PN, Knigge U, Warberg J, Svendsen I, et al. (1995) Role of glucagon in maintenance of euglycemia in fed and fasted rats. Am J Physiol 269: E469-477.
13. Brand CL, Jorgensen PN, Svendsen I, Holst JJ, (1996) Evidence for a major role for glucagon in regulation of plasma glucose in conscious, nondiabetic, and alloxan-induced diabetic rabbits. Diabetes 45: 1076-1083.
14. Brand CL, Rolin B, Jorgensen PN, Svendsen I, Kristensen JS, et al. (1994) Immunoneutralization of endogenous glucagon with monoclonal glucagon antibody normalizes hyperglycaemia in moderately streptozotocin-diabetic rats. Diabetologia 37: 985-993.
15. Liang Y, Osborne MC, Monia BP, Bhanot S, Gaarde WA, et al. (2004) Reduction in glucagon receptor expression by an antisense oligonucleotide ameliorates diabetic syndrome in db/db mice. Diabetes 53: 410-417.
16. Sloop KW, Cao JX, Siesky AM, Zhang HY, Bodenmiller DM, et al. (2004) Hepatic and glucagon-like peptide-1-mediated reversal of diabetes by glucagon receptor antisense oligonucleotide inhibitors. J Clin Invest 113: 1571-1581.
17. Johnson DG, Goebel CU, Hruby VJ, Bregman MD, Trivedi D, (1982) Hyperglycemia of diabetic rats decreased by a glucagon receptor antagonist. Science 215: 1115-1116.
18. Unson CG, Gurzenda EM, Merrifield RB, (1989) Biological activities of des-His1[Glu9]glucagon amide, a glucagon antagonist. Peptides 10: 1171-1177.
19. Qureshi SA, Rios Candelore M, Xie D, Yang X, Tota LM, et al. (2004) A novel glucagon receptor antagonist inhibits glucagon-mediated biological effects. Diabetes 53: 3267-3273.
20. Dallas-Yang Q, Shen X, Strowski M, Brady E, Saperstein R, et al. (2004) Hepatic glucagon receptor binding and glucose-lowering in vivo by peptidyl and non-peptidyl glucagon receptor antagonists. Eur J Pharmacol 501: 225-234.
21. Hancock AS, Du A, Liu J, Miller M, May CL, (2010) Glucagon deficiency reduces hepatic glucose production and improves glucose tolerance in adult mice. Mol Endocrinol 24: 1605-1614.
22. Maximov A, Lao Y, Li H, Chen X, Rizo J, et al. (2008) Genetic analysis of synaptotagmin-7 function in synaptic vesicle exocytosis. Proc Natl Acad Sci U S A 105: 3986-3991.
23. Lou PH, Yang G, Huang L, Cui Y, Pourbahrami T, et al. (2010) Reduced body weight and increased energy expenditure in transgenic mice over-expressing soluble leptin receptor. PLoS One 5: e11669.
24. Butler AA, Kozak LP, (2010) A recurring problem with the analysis of energy expenditure in genetic models expressing lean and obese phenotypes. Diabetes 59: 323-329.
25. Bligh EG, Dyer WJ, (1959) A rapid method of total lipid extraction and purification. Can J Biochem Physiol 37: 911-917.
26. Cadenas S, Echtay KS, Harper JA, Jekabsons MB, Buckingham JA, et al. (2002) The basal proton conductance of skeletal muscle mitochondria from transgenic mice overexpressing or lacking uncoupling protein-3. J Biol Chem 277: 2773-2778.
27. Watt MJ, Holmes AG, Pinnamaneni SK, Garnham AP, Steinberg GR, et al. (2006) Regulation of HSL serine phosphorylation in skeletal muscle and adipose tissue. Am J Physiol Endocrinol Metab 290: E500-508.
28. Degerman E, Smith CJ, Tornqvist H, Vasta V, Belfrage P, et al. (1990) Evidence that insulin and isoprenaline activate the cGMP-inhibited low-Km cAMP phosphodiesterase in rat fat cells by phosphorylation. Proc Natl Acad Sci U S A 87: 533-537.
29. Anthonsen MW, Ronnstrand L, Wernstedt C, Degerman E, Holm C, (1998) Identification of novel phosphorylation sites in hormone-sensitive lipase that are phosphorylated in response to isoproterenol and govern activation properties in vitro. J Biol Chem 273: 215-221.
30. Rasmussen BB, Wolfe RR, (1999) Regulation of fatty acid oxidation in skeletal muscle. Annu Rev Nutr 19: 463-484.
31. Bruce CR, Brolin C, Turner N, Cleasby ME, van der Leij FR, et al. (2007) Overexpression of carnitine palmitoyltransferase I in skeletal muscle in vivo increases fatty acid oxidation and reduces triacylglycerol esterification. Am J Physiol Endocrinol Metab 292: E1231-1237.
32. Barger JL, Barnes BM, Boyer BB, (2006) Regulation of UCP1 and UCP3 in arctic ground squirrels and relation with mitochondrial proton leak. J Appl Physiol 101: 339-347.
33. Han W, Rhee JS, Maximov A, Lao Y, Mashimo T, et al. (2004) N-glycosylation is essential for vesicular targeting of synaptotagmin 1. Neuron 41: 85-99.
34. Unger RH, Orci L, (1975) The essential role of glucagon in the pathogenesis of diabetes mellitus. Lancet 1: 14-16.
35. Clapham JC, Arch JR, Chapman H, Haynes A, Lister C, et al. (2000) Mice overexpressing human uncoupling protein-3 in skeletal muscle are hyperphagic and lean. Nature 406: 415-418.
36. Millet L, Vidal H, Andreelli F, Larrouy D, Riou JP, et al. (1997) Increased uncoupling protein-2 and-3 mRNA expression during fasting in obese and lean humans. J Clin Invest 100: 2665-2670.
37. Boss O, Samec S, Desplanches D, Mayet MH, Seydoux J, et al. (1998) Effect of endurance training on mRNA expression of uncoupling proteins 1, 2, and 3 in the rat. FASEB J 12: 335-339.
38. Cortright RN, Zheng D, Jones JP, Fluckey JD, DiCarlo SE, et al. (1999) Regulation of skeletal muscle UCP-2 and UCP-3 gene expression by exercise and denervation. Am J Physiol 276: E217-221.
39. Gong DW, He Y, Reitman ML, (1999) Genomic organization and regulation by dietary fat of the uncoupling protein 3 and 2 genes. Biochem Biophys Res Commun 256: 27-32.
40. Bezaire V, Spriet LL, Campbell S, Sabet N, Gerrits M, et al. (2005) Constitutive UCP3 overexpression at physiological levels increases mouse skeletal muscle capacity for fatty acid transport and oxidation. FASEB J 19: 977-979.
41. Garcia-Martinez C, Sibille B, Solanes G, Darimont C, Mace K, et al. (2001) Overexpression of UCP3 in cultured human muscle lowers mitochondrial membrane potential, raises ATP/ADP ratio, and favors fatty acid vs. glucose oxidation. FASEB J 15: 2033-2035.
42. Harper ME, Green K, Brand MD, (2008) The efficiency of cellular energy transduction and its implications for obesity. Annu Rev Nutr 28: 13-33.
43. Bartness TJ, Bamshad M, (1998) Innervation of mammalian white adipose tissue: implications for the regulation of total body fat. Am J Physiol 275: R1399-1411.
44. Jocken JW, Blaak EE, (2008) Catecholamine-induced lipolysis in adipose tissue and skeletal muscle in obesity. Physiol Behav 94: 219-230.
45. Schonn JS, Maximov A, Lao Y, Sudhof TC, Sorensen JB, (2008) Synaptotagmin-1 and-7 are functionally overlapping Ca2+ sensors for exocytosis in adrenal chromaffin cells. Proc Natl Acad Sci U S A 105: 3998-4003.